Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
|Articles|May 1, 2008
- Volume 0 0
recruitment/RESOURCES
Advertisement
Articles in this issue
over 18 years ago
advertiserINDEXover 18 years ago
productHOTLINEover 18 years ago
Motion Sickness: Calming the Waves of Upsetover 18 years ago
pharmacy Pet Peevesover 18 years ago
canyouREADtheseRxs?over 18 years ago
Case Studiesover 18 years ago
DIABETESWATCHover 18 years ago
CHOLESTEROLWATCHover 18 years ago
compoundingHOTLINEover 18 years ago
ARTHRITISWATCHAdvertisement
Related to this article
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
2
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
3
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
4
Comparison of Weight-Based vs Non–Weight-Based Norepinephrine Dosing in Patients With Septic Shock
5